시장보고서
상품코드
1148956

세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장 : 기회와 전략(-2031년)

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 252 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 아달리무맙(Adalimumab)·인플릭시맵(Infliximab)·에타너셉트(Etanercept) 바이오시밀러 시장을 조사했으며, 시장 개요, 시장 규모와 예측, 동향, 성장 촉진요인 및 억제요인, 제품별·용도별·유통 채널별·지역별 분석 등의 정보를 제공합니다.

목차

제1장 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장 개요

제2장 목차

제3장 그림 리스트

제4장 표 리스트

제5장 보고서의 구조

제6장 서론과 시장의 특징

  • 일반적인 시장의 정의
  • 개요
  • 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장의 정의와 세분화
  • 시장 세분화 : 제품별
    • 아달리무맙 바이오시밀러
    • 인플릭시맵 바이오시밀러
    • 에타너셉트 바이오시밀러
  • 시장 세분화 : 용도별
    • 크론병
    • 건선성 관절염
    • 류마티스 관절염
    • 궤양성 대장염
    • 강직성 척추염
    • 심상성 건선
    • 기타 용도
  • 시장 세분화 : 유통 채널별
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제7장 주요 시장 동향

  • 마켓 플레이스에서의 격렬한 경쟁
  • 인수합병(M&A) 증가
  • FDA 규제 개정에 의해 바이오시밀러 의약품 개발을 촉진
  • 다수의 전략적 파트너십
  • 바이오시밀러 시장에 대한 투자 증가

제8장 세계 시장 규모와 성장

  • 시장 규모
  • 시장 성장 실적(2016-2021년)
    • 시장 성장 촉진요인(2016-2021년)
    • 시장 성장 억제요인(2016-2021년)
  • 시장 성장 예측(2021-2026년, 2031년)
    • 시장 성장 촉진요인(2021-2026년)
    • 시장 성장 억제요인(2021-2026년)

제9장 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장, 지역 분석

  • 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장, 지역별, 실적과 예측(2016-2021년, 2026년, 2031년)
  • 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장, 국가별, 실적과 예측(2016-2021년, 2026년, 2031년)

제10장 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장 세분화

  • 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장, 제품별 세분화, 실적과 예측(2016-2021년, 2026년, 2031년)
  • 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장, 용도별 세분화, 실적과 예측(2016-2021년, 2026년, 2031년)
  • 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장, 유통 채널별 세분화, 실적과 예측(2016-2021년, 2026년, 2031년)

제11장 아시아태평양 시장

제12장 서유럽 시장

제13장 동유럽 시장

제14장 북미 시장

제15장 남미 시장

제16장 중동 시장

제17장 아프리카 시장

제18장 경쟁 구도와 기업 개요

제19장 기업 개요

  • Biogen
    • 기업 개요
    • 제품 및 서비스
    • 사업 전략
    • 재무 상황 개요
  • Novartis AG(Sandoz)
    • 기업 개요
    • 제품 및 서비스
    • 사업 전략
    • 재무 상황 개요
  • Pfizer Inc.
    • 기업 개요
    • 제품 및 서비스
    • 사업 전략
    • 재무 상황 개요
  • Amgen Inc
    • 기업 개요
    • 제품 및 서비스
    • 사업 전략
    • 재무 상황 개요
  • Celltrion
    • 기업 개요
    • 제품 및 서비스
    • 사업 전략
    • 재무 상황 개요

제20장 파이프라인 분석

제21장 시장의 주요 인수합병(M&A)

제22장 세계의 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장 : 기회와 전략

제23장 아달리무맙/인플릭시맵/에타너셉트 바이오시밀러 시장 : 결론 및 제안

제24장 부록

LSH 22.11.18

“Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031 ” from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global adalimumab, infliximab and etanercept biosimilars market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? “The adalimumab, infliximab and etanercept biosimilars market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider adalimumab, infliximab and etanercept biosimilars market; and compares it with other markets.

The report covers the following chapters:

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about adalimumab, infliximab and etanercept biosimilars market.
  • Key Trends - Highlights the major trends shaping the global adalimumab, infliximab and etanercept biosimilars market. This section also highlights likely future developments in the market.
  • Global Market Size and Growth - Global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - Historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region.
  • Market Segmentation - Contains the market values (2016-2031) and analysis for for segment by product, by application, and by distribution channel in the market.
  • Regional Market Size and Growth - Regional market size (2021), historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Pipeline Analysis - Briefs on the pipeline analysis of adalimumab, infliximab and etanercept biosimilars from the major players in the market.
  • Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations - Includes recommendations for adalimumab, infliximab and etanercept biosimilars providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

  • 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
  • 2) By Application: Crohn's Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion
  • Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; adalimumab, infliximab and etanercept biosimilars indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Adalimumab, Infliximab And Etanercept Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction and Market Characteristics

  • 6.1. General Market Definition
  • 6.2. Summary
  • 6.3. Adalimumab, Infliximab And Etanercept Biosimilars Market Definition and Segmentations
  • 6.4. Market Segmentation By Product
    • 6.4.1. Adalimumab Biosimilars
    • 6.4.2. Infliximab Biosimilars
    • 6.4.3. Etanercept Biosimilars
  • 6.5. Market Segmentation By Application
    • 6.5.1. Crohn's Disease
    • 6.5.2. Psoriatic Arthritis
    • 6.5.3. Rheumatoid Arthritis
    • 6.5.4. Ulcerative Colitis
    • 6.5.5. Ankylosing Spondylitis
    • 6.5.6. Plaque Psoriasis
    • 6.5.7. Other Applications
  • 6.6. Market Segmentation By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies
    • 6.6.3. Online Pharmacies

7. Major Market Trends

  • 7.1. Robust Competition in the Marketplace
  • 7.2. Growing Mergers And Acquisitions
  • 7.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development
  • 7.4. Large Number Of Strategic Partnerships
  • 7.5. Increasing Investments In Biosimilars Market

8. Global Market Size And Growth

  • 8.1. Market Size
  • 8.2. Historic Market Growth, 2016 - 2021, Value ($ Million)
    • 8.2.1. Market Drivers 2016 - 2021
    • 8.2.2. Market Restraints 2016 - 2021
  • 8.3. Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
    • 8.3.1. Market Drivers 2021 - 2026
    • 8.3.2. Market Restraints 2021 - 2026

9. Adalimumab, Infliximab and Etanercept Biosimilars Market, Regional Analysis

  • 9.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 9.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

10. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

  • 10.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 10.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 10.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distributional Channel, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

11. Asia-Pacific Market

  • 11.1. Summary
  • 11.2. Asia Pacific Market Overview
    • 11.2.1. Region Information
    • 11.2.2. Market Information
    • 11.2.3. Background Information
    • 11.2.4. Government Initiatives
    • 11.2.5. Regulations
    • 11.2.6. Regulatory Bodies
    • 11.2.7. Major Associations
    • 11.2.8. Taxes Levied
    • 11.2.9. Corporate Tax Structure
    • 11.2.10. Investments
    • 11.2.11. Major Companies
  • 11.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.5. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 11.6. Asia Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
  • 11.7. China Market
  • 11.8. Summary
  • 11.9. China Market Overview
    • 11.9.1. Country Information
    • 11.9.2. Market Information
    • 11.9.3. Background Information
    • 11.9.4. Government Initiatives
    • 11.9.5. Regulations
    • 11.9.6. Regulatory Bodies
    • 11.9.7. Major Associations
    • 11.9.8. Taxes Levied
    • 11.9.9. Corporate Tax Structure
    • 11.9.10. Investments
    • 11.9.11. Major Companies
  • 11.10. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.11. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.12. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 11.13. India Market
  • 11.14. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.15. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.16. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 11.17. Japan Market
  • 11.18. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.19. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.20. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 11.21. Australia Market
  • 11.22. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.23. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.24. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 11.25. Indonesia Market
  • 11.26. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.27. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.28. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 11.29. South Korea Market
  • 11.30. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 11.31. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 11.32. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

12. Western Europe Market

  • 12.1. Summary
  • 12.2. Western Europe Market Overview
    • 12.2.1. Region Information
    • 12.2.2. Market Information
    • 12.2.3. Background Information
    • 12.2.4. Government Initiatives
    • 12.2.5. Regulations
    • 12.2.6. Regulatory bodies
    • 12.2.7. Major Associations
    • 12.2.8. Taxes Levied
    • 12.2.9. Corporate Tax Structure
    • 12.2.10. Investments
    • 12.2.11. Major Companies
  • 12.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 12.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 12.5. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 12.6. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
  • 12.7. UK Market
  • 12.8. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 12.9. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 12.10. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 12.11. Germany Market
  • 12.12. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 12.13. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 12.14. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 12.15. France Market
  • 12.16. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 12.17. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 12.18. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

13. Eastern Europe Market

  • 13.1. Summary
  • 13.2. Eastern Europe Market Overview
    • 13.2.1. Region Information
    • 13.2.2. Market Information
    • 13.2.3. Background Information
    • 13.2.4. Government Initiatives
    • 13.2.5. Regulations
    • 13.2.6. Regulatory Bodies
    • 13.2.7. Major Associations
    • 13.2.8. Taxes Levied
    • 13.2.9. Corporate Tax Structure
    • 13.2.10. Investments
    • 13.2.11. Major Companies
  • 13.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 13.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 13.5. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 13.6. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
  • 13.7. Russia Market
  • 13.8. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 13.9. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 13.10. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

14. North America Market

  • 14.1. Summary
  • 14.2. North America Market Overview
    • 14.2.1. Region Information
    • 14.2.2. Market Information
    • 14.2.3. Background Information
    • 14.2.4. Government Initiatives
    • 14.2.5. Regulations
    • 14.2.6. Regulatory Bodies
    • 14.2.7. Major Associations
    • 14.2.8. Taxes Levied
    • 14.2.9. Corporate tax structure
    • 14.2.10. Investments
    • 14.2.11. Major Companies
  • 14.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 14.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 14.5. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 14.6. North America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
  • 14.7. USA Market
  • 14.8. Summary
  • 14.9. USA Market Overview
    • 14.9.1. Country Information
    • 14.9.2. Market Information
    • 14.9.3. Background Information
    • 14.9.4. Government Initiatives
    • 14.9.5. Regulations
    • 14.9.6. Regulatory Bodies
    • 14.9.7. Major Associations
    • 14.9.8. Taxes Levied
    • 14.9.9. Corporate Tax Structure
    • 14.9.10. Investments
    • 14.9.11. Major Companies
  • 14.10. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 14.11. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 14.12. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

15. South America Market

  • 15.1. Summary
  • 15.2. South America Market Overview
    • 15.2.1. Region Information
    • 15.2.2. Market Information
    • 15.2.3. Background Information
    • 15.2.4. Government Initiatives
    • 15.2.5. Regulations
    • 15.2.6. Regulatory Bodies
    • 15.2.7. Major Associations
    • 15.2.8. Taxes Levied
    • 15.2.9. Corporate Tax Structure
    • 15.2.10. Investments
    • 15.2.11. Major Companies
  • 15.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 15.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 15.5. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
  • 15.6. South America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
  • 15.7. Brazil Market
  • 15.8. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 15.9. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 15.10. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

16. Middle East Market

  • 16.1. Summary
  • 16.2. Middle East Market Overview
    • 16.2.1. Region Information
    • 16.2.2. Market Information
    • 16.2.3. Background Information
    • 16.2.4. Government Initiatives
    • 16.2.5. Regulations
    • 16.2.6. Regulatory Bodies
    • 16.2.7. Major Associations
    • 16.2.8. Taxes Levied
    • 16.2.9. Corporate Tax Structure
    • 16.2.10. Investments
    • 16.2.11. Major Companies
  • 16.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 16.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 16.5. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

17. Africa Market

  • 17.1. Summary
  • 17.2. Africa Market Overview
    • 17.2.1. Region Information
    • 17.2.2. Market Information
    • 17.2.3. Background Information
    • 17.2.4. Government Initiatives
    • 17.2.5. Regulations
    • 17.2.6. Regulatory Bodies
    • 17.2.7. Major Associations
    • 17.2.8. Taxes Levied
    • 17.2.9. Corporate Tax Structure
    • 17.2.10. Investments
    • 17.2.11. Major Companies
  • 17.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
  • 17.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
  • 17.5. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)

18. Competitive Landscape And Company Profiles

19. Company Profiles

  • 19.1. Biogen
    • 19.1.1. Company Overview
    • 19.1.2. Products And Services.
    • 19.1.3. Business Strategy
    • 19.1.4. Financial Overview
  • 19.2. Novartis AG (Sandoz)
    • 19.2.1. Company Overview
    • 19.2.2. Products And Services.
    • 19.2.3. Business Strategy
    • 19.2.4. Financial Overview
  • 19.3. Pfizer Inc.
    • 19.3.1. Company Overview
    • 19.3.2. Products And Services
    • 19.3.3. Business Strategy
    • 19.3.4. Financial Overview
  • 19.4. Amgen Inc
    • 19.4.1. Company Overview
    • 19.4.2. Products And Services.
    • 19.4.3. Business Strategy
    • 19.4.4. Financial Overview
  • 19.5. Celltrion
    • 19.5.1. Company Overview
    • 19.5.2. Products And Services
    • 19.5.3. Business Strategy
    • 19.5.4. Financial Overview

20. Pipeline Analysis

21. Key Mergers And Acquisitions In The Market

  • 21.1. Fresenius Kabi Acquired mAbxience
  • 21.2. Biocon Biologics to Acquire Viatris Biosimilars Business
  • 21.3. Celltrion Acquired Assets Of Takeda Pharmaceuticals
  • 21.4. Amgen Acquired Japanese JV with Astellas
  • 21.5. True North Acquired Stake In Biocon Biologics Ltd.
  • 21.6. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India
  • 21.7. Ligand Pharmaceuticals Acquired Pfenex
  • 21.8. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.
  • 21.9. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital
  • 21.10. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech
  • 21.11. Biocon Merged With Sandoz

22. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Opportunities And Strategies

  • 22.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 - Countries Offering Most New Opportunities
  • 22.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 - Segments Offering Most New Opportunities
  • 22.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market In 2026 - Growth Strategies
    • 22.3.1. Market Trend Based Strategies
    • 22.3.2. Competitor Strategies

23. Adalimumab, Infliximab and Etanercept Biosimilars Market, Conclusions And Recommendations

  • 23.1. Conclusions
  • 23.2. Recommendations
    • 23.2.1. Product
    • 23.2.2. Place
    • 23.2.3. Price
    • 23.2.4. Promotion
    • 23.2.5. People

24. Appendix

  • 24.1. Market Data Sources
  • 24.2. Research Methodology
  • 24.3. Currencies
  • 24.4. The Business Research Company
  • 24.5. Copyright and Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제